Fall Skin Care Sale

Life Extension Magazine

LE Magazine September 2005

image

How Many Americans Are Magnesium Deficient?

CALCULATING AMERICAN DEATHS
CAUSED BY MAGNESIUM DEFICIENCY

“Magnesium deficiency appears to have caused 8 million sudden coronary deaths in America during the period 1940-1994 . . . The needless drag on the US economy from magnesium deficiency exceeds $86 billion per year . . . the American rate of death from magnesium deficiency is likely to be above the benchmark average because the American diet is particularly magnesium deficient; American beer contains only a fraction of the magnesium contained in European beers; American bottled water contains only 10% as much magnesium as bottled water in the rest of the world; and American processed foods and snack foods are magnesium-deficient because processing often removes magnesium.145

—Paul Mason

Defying the Critics

Since 1981, Life Extension has recommended high-potency magnesium supplements, because magnesium is perhaps the most deficient mineral in the American diet.

With all the research linking low magnesium intake with high cardiovascular risks, this low-cost mineral would appear to be a simple way to counter today’s heart attack and stroke epidemic. Unfortunately, magnesium is so cheap that virtually no one is promoting it as a lifesaving mineral.

In the early 1980s, the Life Extension Foundation was criticized by mainstream doctors for recommending high doses of magnesium relative to calcium. We even had our magnesium supplements seized by the FDA because we presented evidence that this mineral could help prevent heart attack.

Medical ignorance continues to be the number-one cause of death. As a Life Extension member, you are regularly informed about scientific discoveries that can enable you to avoid becoming a casualty of today’s broken health care system. Those who follow our basic supplement program obtain 325-665 mg of supplemental magnesium each day.

We commend Paul Mason for his meticulous compilation of data showing that millions of people are dying each year from the effects of magnesium deficiency. We view Paul as an unsung hero for his battle to enlighten the world about these startling statistics. Perhaps one day the medical community will listen.

For longer life,
image

William Faloon

Rate Your Bottled Water

The table below of America’s 10 leading bottled waters shows how many lives might be saved if these brands either switched to springs that are naturally rich in magnesium or fortified their water with magnesium.

BEVERAGE WORLD Top 10 Bottled Waters of 1999

RANK

BRAND

SALES (millions)

MARKET SHARE

ESTIMATED GALLONS
(millions)

MAGNESIUM mg/liter

COUNTRY
OF ORIGIN

ESTIMATED
LIVES SAVED
PER YEAR
if water had
90 mg/liter
magnesium

1

Poland Spring

$406.2

8.2%

278.8

2

US

1,242

2

Arrowhead

$315.0

6.4%

217.6

5

US

937

3

Aquafina

$285.0

5.8%

197.2

22

Canada

679

4

Sparkletts

$246.5

5.0%

170.0

5

US

731

5

Evian

$219.0

4.4%

149.6

24

France

500

6

Deer Park

$167.4

3.4%

115.6

1

US

521

8

Zephyrhills

$147.5

3.0%

102.0

7

US

428

9

Ozarka

$144.6

2.9%

98.6

1

US

444

10

Hinckley Springs*

$134.2

2.7%

91.8

?

US

?

 

TOP 10 BRANDS

$2,216.8

44.9%

1,526.6

8.4 mg/L

80% US

6,308

 

All Brands

$4,900.0

100.0%

3,400.0

2.7 mg/L

Mostly US

15,032

The bottled water with the highest magnesium content (110 mg/liter) is sold under the brand name
“Noah’s Spring Water.” Unfortunately, distribution of this brand of bottled water is limited to certain parts of California.144
*Formerly known as Hinckley & Schmitt. NOTE: Sales figures preliminary. SOURCE: Beverage Marketing Corporation.

References

1. District Court of The United States, Northern District of California, Paul W. Mason, Plaintiff vs. Donna Shalala, Secretary of Health and Human Services, and Dr. Michael Friedman, Acting Commissioner of the U.S. Food and Drug Administration, Defendants. CASE NO. C97-20686 RMW.

2. Available at: http://www.saltinstitute.org /idd.html. Accessed June 6, 2005.

3. Available at: http://www.mayoclinic.com/invoke.cfm?id=DS00217. Accessed June 6, 2005.

4. Brush B, Altland J. Goiter prevention with iodized salt: results of a thirty-year study. J Clin Endocrinol Metab. 1952 Oct;12(10):1380-8.

5. Kimball OP. The efficiency and safety of the prevention of goiter. JAMA. 1928 91:454-60.

6. Available at: http://www.mgwater.com. Accessed June 6, 2005.

7. Joffres MR, Reed DM, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am J Clin Nutr. 1987 Feb;45(2):469-75.

8. Singh R, Sircar A, Rastogi S, Singh R. Dietary modulators of blood pressure in hypertension. Eur J Clin Nutr. 1990 Apr;44(4):319-27.

9. Peacock J, Folsom A, Arnett D, Eckfeldt J, Szklo M. Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 1999 Apr;9(3):159-65.

10. Ascherio A, Hennekens C, Willett W, et al. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension. 1996 May;27(5):1065-72.

11. Gottlieb S, Fisher M, Pressel M, Patten R, Weinberg M, Greenberg N. Effects of intravenous MAGNESIUM sulfate on arrhythmias in patients with congestive heart failure. Am Heart J. 1993 Jun;125(6):1645-50.

12. Zehender M. Magnesium in supraventricular and ventricular arrhythmias. Z Kardiol. 1996;85 Suppl 6:135-45.

13. Shechter M, Sharir M, Labrador M, Forrester J, Silver B, Bairey Merz C. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation. 2000 Nov 7;102(19):2353-8.

14. Maier J, Malpuech-Brugere C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta. 2004 May 24;1689(1):13-21.

15. Maier J. Low magnesium and atherosclerosis: an evidence-based link. Mol Aspects Med. 2003 Feb-Jun;24(1-3):137-46.

16. Tanabe K, Noda K, Kamegai M, et al. Variant angina due to deficiency of intracellular magnesium. Clin Cardiol. 1990 Sep;13(9):663-5.

17. Ravn H, Korsholm T, Falk E. Oral magnesium supplementation induces favorable antiatherogenic changes in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2001 May;21(5):858-62.

18. Liao F, Folsom A, Brancati F. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1998 Sep;136(3):480-90.

19. Sheu J, Hsiao G, Shen M, Lee Y, Yen M. Antithrombotic effects of magnesium sulfate in in vivo experiments. Int J Hematol. 2003 May;77(4):414-9.

20. Mussoni L, Sironi L, Tedeschi L, Calvio A, Colli S, Tremoli E. Magnesium inhibits arterial thrombi after vascular injury in rat: in vivo impairment of coagulation. Thromb Haemost. 2001 Nov;86(5):1292-5.

21. Shechter M. The role of magnesium as antithrombotic therapy. Wien Med Wochenschr. 2000;150(15-16):343-7.

22. Toft G, Ravn H, Hjortdal V. Intravenously and topically applied magnesium in the prevention of arterial thrombosis. Thromb Res. 2000 Jul 1;99(1):61-9.

23. Whang, R. Electrolyte and water metabolism in sports activities. Compr Ther. 1998 Jan;24(1):5-8.

24. Shechter M, Bairey Merz C, Stuehlinger H, Slany J, Pachinger O, Rabinowitz B. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol. 2003 Mar 1;91(5):517-21.

25. Geiss K, Stergiou N, Jester, Neuenfeld H, Jester H. Effects of magnesium orotate on exercise tolerance in patients with coronary heart disease. Cardiovasc Drugs Ther. 1998 Sep;12 Suppl 2:153-6.

26. Smetana R, Wink K. Magnesium, acute myocardial infarction and reperfusion injury. Clin Calcium. 2005 Feb;15(2):261-4.

27. Shechter M, Hod H, Rabinowitz B, Boyko V, Chouraqui P. Long-term outcome of intravenous magnesium therapy in thrombolysis-ineligible acute myocardial infarction patients. Cardiology. 2003;99(4):205-10.

28. Chiu H, Chen C, Tsai S, Wu T, Yang C. Relationship between magnesium levels in drinking water and sudden infant death syndrome. Magnes Res. 2005 Mar;18(1):12-8.

29. Leary W, Reyes A. Magnesium and sudden death. S Afr Med J. 1983 Oct 22;64(18):697-8.

30. Douban S, Brodsky M, Whang D, Whang R. Significance of magnesium in congestive heart failure. Am Heart J. 1996 Sep;132(3):664-71.

31. Available at: http://www.seattlechildrens.org/ home/about_childrens/press_releases/000100.asp. Accessed June 6, 2005.

32. Schmitz C, Perraud A, Johnson C, et al. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell. 2003 Jul 25;114(2):191-200.

33. Available at: http://www.mgwater.com/ heart.shtml. Accessed June 6, 2005.

34. King D, Mainous A 3rd, Geesey M, Woolson R. Dietary magnesium and C-reactive protein levels. J Am Coll Nutr. 2005 Jun 24(3):166-71.

35. Available at: http://ods.od.nih.gov/factsheets/magnesium.asp. Accessed June 6, 2005.

36. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA. 2002 Aug 28;288(8):980-7.

37. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation. 2002 Sep 3;106(10):1224-8.

38. Wang TJ, Larson MG, Levy D, et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation. 2002 Sep 3;106(10):1189-91.

39. Kanda T. C-reactive protein (CRP) in the cardiovascular system. Rinsho Byori. 2001 Apr;49(4):395-401.

40. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 Apr 3;336(14):973-9.

41. Auer J, Berent R, Lassnig E, Eber B. C-reactive protein and coronary artery disease. Jpn Heart J. 2002 Nov;43(6):607-19.

42. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998 Aug 25;98(8):731-3.

43. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001 Jan;32(1):133-8.

44. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999 May;106(5):506-12.

45. Invitti C. Obesity and low-grade systemic inflammation. Minerva Endocrinol. 2002 Sep;27(3):209-14.

46. Sitzer M, Markus HS, Mendall MA, et al. C-reactive protein and carotid intimal medial thickness in a community population. J Cardiovasc Risk. 2002 Apr;9(2):97-103.

47. Teunissen CE, van Boxtel MP, Bosma H, et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol. 2003 Jan;134(1-2):142-50.

48. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000 Oct;21(19):1584-90.

49. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000 Oct 31;102(18):2165-8.

50. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998 Feb 10;97(5):425-8.

51. Rifai N. C-reactive protein and coronary heart disease: diagnostic and therapeutic implications for primary prevention. Cardiovasc Toxicol. 2001;1(2):153-7.

52. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001 Apr 3;103(13):1813-8.

53. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001 Mar;47(3):403-11.

54. Available at: http://www.lef.org/magazine/ mag2001/jan2001_awsi.html. Accessed June 6, 2005.

55. Available at: http://www.lef.org/magazine/ mag2000/mar00-report.html. Accessed June 6, 2005.

56. Available at: http://www.lef.org/magazine/ mag2000/july2000_itn.html. Accessed June 6, 2005.

57. Available at: http://www.lef.org/magazine/ mag2001/jan2001_itn.html. Accessed June 6, 2005.

58. Available at: http://www.lef.org/magazine/ mag2000/feb00-report2.html. Accessed June 6, 2005.

59. Available at: http://www.lef.org/magazine/ mag2002/jan2002_awsi_01.html. Accessed June 6, 2005.

60. Brod SA. Unregulated inflammation shortens human functional longevity. Inflamm Res. 2000 Nov;49(11):561-70.

61. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis. 2004 Feb;17(1):35-44.

62. Alvaro-Gonzalez LC, Freijo-Guerrero MM, Sadaba-Garay F. Inflammatory mechanisms, arteriosclerosis and ischemic stroke: clinical data and perspectives. Rev Neurol. 2002 Sep 1;35(5):452-62.

63. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000 Oct 19;343(16):1139-47.

64. Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000 Oct 19;343(16):1148-55.

65. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 2001 Aug 14;104(7):746-9.

66. Devaux B, Scholz D, Hirche A, Klovekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 1997 Mar;18(3):470-9.

67. Santoro A, Mancini E. Cardiac effects of chronic inflammation in dialysis patients. Nephrol Dial Transplant. 2002;17 Suppl 8:10-15.

68. Brouqui P, Dumler JS, Raoult D. Immunohistologic demonstration of Coxiella burnetii in the valves of patients with Q fever endocarditis. Am J Med. 1994 Nov;97(5):451-8.

69. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol. 2002 Dec 15;90(12):1279-83.

70. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park). 2002 Feb;16(2):217-26, 229.

71. Zavros Y, Eaton KA, Kang W, et al. Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. Oncogene. 2005 Mar 31;24(14):2354-66.

72. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer. 2003 Jul;5(1):46-62.

73. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc.). 1998 Jul;63(7):854-65.

74. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999 Jun;5(6):1369-79.

75. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1995 Jul;4(5):447-51.

76. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67.

77. Deeb ZE, Fox LA, deFries HO. The association of chronic inflammatory disease in lichen planus with cancer of the oral cavity. Am J Otolaryngol. 1989 Sep;10(5):314-6.

78. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10 Suppl 4:308-11.

79. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990 Nov 1;323(18):1228-33.

80. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J. 1997 May;11(6):457-65.

81. Grisham M, Jourd’heuil D, Wink D. Review article: chronic inflammation and reactive oxygen and nitrogen metabolism—implications in DNA damage and mutagenesis. Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:3-9.

82. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996 Jan 1;313 (Pt 1)17-29.

83. Wenk GL, McGann K, Hauss-Wegrzyniak B, Rosi S. The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer’s disease. Neuroscience. 2003;121(3):719-29.

84. Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002 Aug;52(2):168-74.

85. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ. 2003 Jul 19;327(7407):128.

86. Stephenson J. More evidence links NSAID, estrogen use with reduced Alzheimer risk. JAMA. 1996 May 8;275(18):1389-90.

87. Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology. 1995 Jan;45(1):51-5.

88. Emsley HC, Tyrrell PJ. Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab. 2002 Dec;22(12):1399-419.

89. Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med. 2002 Nov 11;162(20):2333-41.

90. De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):785-813.

91. Guebre-Egziabher F, Fouque D. Metabolic consequences of inflammation in kidney failure. Nephrologie. 2003;24(7):383-6.

92. Tomita M, Holman BJ, Williams LS, Pang KC, Santoro TJ. Cerebellar dysfunction is associated with overexpression of proinflammatory cytokine genes in lupus. J Neurosci Res. 2001 Apr 1;64(1):26-33.

93. Bruck W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci. 2003 Dec;24 Suppl 5:S265-7.

94. Speer CP. New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate. 2001;79(3-4):205-9.

95. Glabinski AR, O’Bryant S, Selmaj K, Ransohoff RM. CXC chemokine receptors expression during chronic relapsing experimental autoimmune encephalomyelitis. Ann NY Acad Sci. 2000;917:135-44.

96. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AE, Wallace JL. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol. 2001 Jan 1;166(1):552-8.

97. Hogan SP, Mishra A, Brandt EB, et al. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol. 2001 Apr;2(4):353-60.

98. Shiels IA, Taylor SM, Fairlie DP. Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Med Hypotheses. 2000 Feb;54(2):193-7.

99. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999 Jul;4(4):317-27.

100. Willard LB, Hauss-Wegrzyniak B, Wenk GL. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Neuroscience. 1999 Jan;88(1):193-200.

101. Van der Meide PH, Schellekens H. Cytokines and the immune response. Biotherapy. 1996;8(3-4):243-9.

102. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology. 1992 Feb;102(2):720-7.

103. Cominelli F, Dinarello CA. Interleukin-1 in the pathogenesis of and protection from inflammatory bowel disease. Biotherapy. 1989;1(4):369-75.

104. Deon D, Ahmed S, Tai K, et al. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol. 2001 Nov 1;167(9):5395-403.

105. Wu H, Dwyer KM, Fan Z, et al. Dietary fiber and progression of atherosclerosis: the Los Angeles Atherosclerosis Study. Am J Clin Nutr. 2003 Dec;78(6):1085-91.

106. Ajani UA, Ford ES, Mokdad AH. Dietary fiber and C-reactive protein: findings from national health and nutrition examination survey data. J Nutr. 2004 May;134(5):1181-5.

107. King DE, Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. Am J Cardiol. 2003 Dec 1;92(11):1335-9.

108. McCarty MF. Low-insulin-response diets may decrease plasma C-reactive protein by influencing adipocyte function. Med Hypotheses. 2005;64(2):385-7.

109. Bahceci M, Tuzcu A, Canoruc N, et al. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm Res. 2004;62(6):283-7.

110. Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism. 2004 Nov;53(11):1454-61.

111. Salmenniemi U, Ruotsalainen E, Pihlajamaki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004 Dec 21;110(25):3842-8.

112 . Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS. Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA. 2004 Nov 24;292(20):2482-90.

113. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology. 2004 Nov;55(6):589-612.

114. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003 Jul 23;290(4):502-10.

115. Richter V, Purschwitz K, Rassoul F, et al. Effects of diet modification on cardiovascular risk: results from the leipzig wholesome nutrition study. Asia Pac J Clin Nutr. 2004 Aug;13(Suppl):S106.

116. Pirro M, Schillaci G, Savarese G, et al. Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil. 2004 Dec;11(6):497-502.

117. Aronson D, Sella R, Sheikh-Ahmad M, et al. The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. J Am Coll Cardiol. 2004 Nov 16;44(10):2003-7.

118. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol. 1993 Dec;169(6):1536-9.

119. Kipper-Galperin M, Galilly R, Danenberg HD, Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor alpha and interleukin-6 [correction of interlukin-6] in astrocytes. Int J Dev Neurosci. 1999 Dec;17(8):765-75.

120. Bellinghieri G, Santoro D, Calvani M, Savica V. Role of carnitine in modulating acute-phase protein synthesis in hemodialysis patients. J Ren Nutr. 2005 Jan;15(1):13-7.

121. Savica V, Calvani M, Benatti P, et al. Carnitine system in uremic patients: molecular and clinical aspects. Semin Nephrol. 2004 Sep;24(5):464-8.

122. Jiang Q, Ames BN. Gamma-tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J. 2003 May;17(8):816-22.

123. Himmelfarb J, Kane J, McMonagle E, et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int. 2003 Sep;64(3):978-91.

124. Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med. 2000 Oct 15;29(8):790-2.

125. Jialal I, Devaraj S, Venugopal SK. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. Free Radic Res. 2002 Dec;36(12):1331-6.

126. Patrick L, Uzick M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev. 2001 Jun;6(3):248-71.

127. Upritchard JE, Sutherland WH, Mann JI. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care. 2000 Jun;23(6):733-8.

128. Wang XL, Rainwater DL, Mahaney MC, Stocker R. Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons. Am J Clin Nutr. 2004 Sep;80(3):649-55.

129. Murphy RT, Foley JB, Tome MT, et al. Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes. Free Radic Biol Med. 2004 Apr 15;36(8):959-65.

130. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002 Apr 23;105(16):1897-903.

131. Lopez-Garcia E, Schulze MB, Manson JE, et al. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr. 2004 Jul;134(7):1806-11.

132. Pischon T, Hankinson SE, Hotamisligil GS, et al. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003 Jul 15;108(2):155-60.

133. Madsen T, Skou HA, Hansen VE, et al. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol. 2001 Nov 15;88(10):1139-42.

134. Ciubotaru I, Lee YS, Wander RC. Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem. 2003 Sep;14(9):513-21.

135. Trebble TM, Arden NK, Wootton SA, et al. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr. 2004 Nov;80(5):1137-44.

136. Jellema A, Plat J, Mensink RP. Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest. 2004 Nov;34(11):766-73.

137. Nestel P, Shige H, Pomeroy S, et al. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr. 2002 Aug;76(2):326-30.

138. Chin JP, Dart AM. HBPRCA Astra Award. Therapeutic restoration of endothelial function in hypercholesterolaemic subjects: effect of fish oils. Clin Exp Pharmacol Physiol. 1994 Oct;21(10):749-55.

139. Paquette DW. The periodontal-cardiovascular link. Compend Contin Educ Dent. 2004 Sep;25(9):681-92.

140. Available at: http://www.latimes.com/features/health/la-he stroke28mar28,1,3986403.story?ctrack=1&cset=true. Accessed June 6, 2005.

141. Available at: http://www.mgwater.com/calcs.shtml#summary. Accessed June 6, 2005.

142. Available at: www.mgwater.com. Accessed June 6, 2005.

143. Available at: http://www.mgwater.com/adobe.shtml. Accessed June 6, 2005.

144. Available at: http://www.mgwater.com/waters.shtml. Accessed June 6, 2005.

145. Available at: http://www.mgwater.com/calcs.shtml. Accessed June 6, 2005.